Market Cap 623.98M
Revenue (ttm) 30.91M
Net Income (ttm) -209.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -677.68%
Debt to Equity Ratio 1.48
Volume 996,100
Avg Vol 2,537,856
Day's Range N/A - N/A
Shares Out 90.56M
Stochastic %K 32%
Beta 0.26
Analysts Strong Sell
Price Target $14.75

Company Profile

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small mole...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 292 4200
Address:
117 Kendrick Street, Suite 500, Needham, United States
sweddle
sweddle Aug. 24 at 1:51 PM
0 · Reply
sweddle
sweddle Aug. 24 at 11:47 AM
0 · Reply
LabPsycho
LabPsycho Aug. 23 at 2:03 PM
$VSTM More Details mid-September.
0 · Reply
CrozrX
CrozrX Aug. 21 at 11:44 PM
3 · Reply
sweddle
sweddle Aug. 21 at 6:52 PM
0 · Reply
PencilNeckGeek
PencilNeckGeek Aug. 21 at 6:34 PM
$VSTM I remember the good old days when this was above $7
0 · Reply
JBuyer
JBuyer Aug. 21 at 3:15 PM
$ALLO $ONCY $SLS $VSTM The shorting of ground breaking cures for Cancer and Autoimmune diseases should not be allowed- or least until they are profitable for one year. But in my mind, NOT AT ALL!!
2 · Reply
sweddle
sweddle Aug. 21 at 2:56 PM
0 · Reply
uzi121314
uzi121314 Aug. 21 at 12:57 PM
$VSTM when 20 usd?
1 · Reply
Always_neutral
Always_neutral Aug. 21 at 3:10 AM
$VSTM Are we down because of it, it doesn't make sense? mPFS is a bit lower than zolda but they have only 27 patients (no doxe) whereas GENFLEET used 57 patients. Higher patient numbers always lower the mPFS. So, I am assuming zolda no better than vs7375 at 600 mg QD. I am pretty sure 900mg would show better results. So, I am a bit confused. Thanks for sharing.
0 · Reply
Latest News on VSTM
Verastem price target lowered to $13 from $14 at Mizuho

2026-08-11T11:32:36.000Z - 13 days ago

Verastem price target lowered to $13 from $14 at Mizuho

VSTM


Verastem price target lowered to $13 from $14 at Mizuho

2026-08-10T17:00:09.000Z - 13 days ago

Verastem price target lowered to $13 from $14 at Mizuho

VSTM


Verastem price target lowered to $12 from $14 at Guggenheim

2026-08-07T11:36:06.000Z - 17 days ago

Verastem price target lowered to $12 from $14 at Guggenheim

VSTM


Verastem Earnings Call Transcript: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 17 days ago

Verastem Earnings Call Transcript: Q2 2026


Verastem Earnings release: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 17 days ago

Verastem Earnings release: Q2 2026


Verastem Quarterly report: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 17 days ago

Verastem Quarterly report: Q2 2026


Verastem Slides: Q2 2026

Aug 6, 2026, 4:30 PM EDT - 17 days ago

Verastem Slides: Q2 2026


Verastem reports Q2 adjusted EPS (31c), consensus (44c)

2026-08-06T20:06:55.000Z - 17 days ago

Verastem reports Q2 adjusted EPS (31c), consensus (44c)

VSTM


Verastem Slides: Corporate presentation

Aug 6, 2026, 7:00 AM EDT - 18 days ago

Verastem Slides: Corporate presentation


Verastem doses first patients in Target-D 203 Phase 2 trial

2026-07-28T20:05:22.000Z - 26 days ago

Verastem doses first patients in Target-D 203 Phase 2 trial

VSTM


Verastem doses first patient in TARGET-D 202 Phase 2 trial

2026-07-22T20:06:33.000Z - 4 weeks ago

Verastem doses first patient in TARGET-D 202 Phase 2 trial

VSTM


Verastem Transcript: Study update

Jun 23, 2026, 4:30 PM EDT - 2 months ago

Verastem Transcript: Study update


Verastem Press release: Study update

Jun 23, 2026, 4:30 PM EDT - 2 months ago

Verastem Press release: Study update


Verastem Slides: Study update

Jun 23, 2026, 4:30 PM EDT - 2 months ago

Verastem Slides: Study update


Verastem price target lowered to $8 from $15 at Jefferies

2026-06-23T17:03:54.000Z - 2 months ago

Verastem price target lowered to $8 from $15 at Jefferies

VSTM


Verastem announces FDA Fast Track designation for VS-7375

2026-06-03T20:06:01.000Z - 2 months ago

Verastem announces FDA Fast Track designation for VS-7375

VSTM


Verastem appoints Michael Bailey to board of directors

2026-05-26T12:54:22.000Z - 3 months ago

Verastem appoints Michael Bailey to board of directors

VSTM


Verastem price target lowered to $14 from $16 at Mizuho

2026-05-14T12:35:05.000Z - 3 months ago

Verastem price target lowered to $14 from $16 at Mizuho

VSTM


Verastem Oncology to Present at Upcoming Investor Conferences

May 12, 2026, 7:30 AM EDT - 3 months ago

Verastem Oncology to Present at Upcoming Investor Conferences

VSTM


Verastem price target lowered to $18 from $19 at BTIG

2026-05-08T12:55:59.000Z - 3 months ago

Verastem price target lowered to $18 from $19 at BTIG

VSTM


Verastem reports Q1 adjusted EPS (43c), consensus (47c)

2026-05-07T21:47:04.000Z - 3 months ago

Verastem reports Q1 adjusted EPS (43c), consensus (47c)

VSTM


Verastem Earnings Call Transcript: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Verastem Earnings Call Transcript: Q1 2026


Verastem Earnings release: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Verastem Earnings release: Q1 2026


Verastem Quarterly report: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Verastem Quarterly report: Q1 2026


Verastem Slides: Q1 2026

May 7, 2026, 4:30 PM EDT - 3 months ago

Verastem Slides: Q1 2026


Verastem Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 4 months ago

Verastem Proxy statement: Proxy filing


Verastem Earnings Call Transcript: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Earnings Call Transcript: Q4 2025


Verastem Earnings release: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Earnings release: Q4 2025


Verastem Annual report: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Annual report: Q4 2025


Verastem Slides: Q4 2025

Mar 4, 2026, 4:30 PM EST - 6 months ago

Verastem Slides: Q4 2025


Verastem Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 9:30 AM EST - 9 months ago

Verastem Transcript: Jefferies London Healthcare Conference 2025


Verastem Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Verastem Earnings Call Transcript: Q3 2025


Verastem Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Verastem Quarterly report: Q3 2025


Verastem Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Verastem Earnings release: Q3 2025


Verastem Registration statement: Registration Filing

Aug 12, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing


Verastem Registration statement: Registration Filing

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing


Verastem Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Verastem Earnings Call Transcript: Q2 2025


Verastem Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Verastem Earnings release: Q2 2025


Verastem Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Verastem Quarterly report: Q2 2025


Verastem Transcript: R&D Day 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Transcript: R&D Day 2025


Verastem Slides: FY 2025

Jun 2, 2025, 12:00 PM EDT - 1 year ago

Verastem Slides: FY 2025


Verastem Registration statement: Registration Filing

May 13, 2025, 8:00 AM EDT - 1 year ago

Verastem Registration statement: Registration Filing


Verastem Earnings release: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Verastem Earnings release: Q1 2025


Verastem Quarterly report: Q1 2025

May 12, 2025, 6:00 PM EDT - 1 year ago

Verastem Quarterly report: Q1 2025


U.S. FDA approves Verastem's cancer therapy

May 8, 2025, 12:23 PM EDT - 1 year ago

U.S. FDA approves Verastem's cancer therapy

VSTM


Verastem Oncology Announces $75 million Private Placement

Apr 25, 2025, 9:00 AM EDT - 1 year ago

Verastem Oncology Announces $75 million Private Placement

VSTM


Verastem Proxy statement: Proxy Filing

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Verastem Proxy statement: Proxy Filing


sweddle
sweddle Aug. 24 at 1:51 PM
0 · Reply
sweddle
sweddle Aug. 24 at 11:47 AM
0 · Reply
LabPsycho
LabPsycho Aug. 23 at 2:03 PM
$VSTM More Details mid-September.
0 · Reply
CrozrX
CrozrX Aug. 21 at 11:44 PM
3 · Reply
sweddle
sweddle Aug. 21 at 6:52 PM
0 · Reply
PencilNeckGeek
PencilNeckGeek Aug. 21 at 6:34 PM
$VSTM I remember the good old days when this was above $7
0 · Reply
JBuyer
JBuyer Aug. 21 at 3:15 PM
$ALLO $ONCY $SLS $VSTM The shorting of ground breaking cures for Cancer and Autoimmune diseases should not be allowed- or least until they are profitable for one year. But in my mind, NOT AT ALL!!
2 · Reply
sweddle
sweddle Aug. 21 at 2:56 PM
0 · Reply
uzi121314
uzi121314 Aug. 21 at 12:57 PM
$VSTM when 20 usd?
1 · Reply
Always_neutral
Always_neutral Aug. 21 at 3:10 AM
$VSTM Are we down because of it, it doesn't make sense? mPFS is a bit lower than zolda but they have only 27 patients (no doxe) whereas GENFLEET used 57 patients. Higher patient numbers always lower the mPFS. So, I am assuming zolda no better than vs7375 at 600 mg QD. I am pretty sure 900mg would show better results. So, I am a bit confused. Thanks for sharing.
0 · Reply
CrozrX
CrozrX Aug. 21 at 1:12 AM
$VSTM Gfh375 (earlier cut-off data abstract) https://cattendee.abstractsonline.com/meeting/21487/Session/129
0 · Reply
CrozrX
CrozrX Aug. 20 at 11:53 PM
$VSTM Gfh375 WCLC26 abstract released. Actual presentation will have updated numbers!
2 · Reply
UnlikelyResult
UnlikelyResult Aug. 20 at 7:22 PM
$VSTM a 10k+ block hasn't traded in over 3 hours, tiddlywinks and penny flipping designed to bore us to death
0 · Reply
sweddle
sweddle Aug. 20 at 6:18 PM
0 · Reply
PencilNeckGeek
PencilNeckGeek Aug. 20 at 6:02 PM
$VSTM Uh oh hope I don't end up regretting not selling my full position yesterday
1 · Reply
sweddle
sweddle Aug. 20 at 4:21 PM
0 · Reply
Marketismanipulated2
Marketismanipulated2 Aug. 20 at 3:34 PM
$VSTM I sold 45k shares when it hit 7.18 and regretted it when it kept climbing, i just bought almost half of them back at $6.83. Hopefully i can purchase the rest back just a little lower and then have it get to 10. Wish i had waited even one more day to have sold but getting another opportunity here.
0 · Reply
NYBomba
NYBomba Aug. 20 at 2:33 PM
$VSTM - as you can see from the attached photo, the current chart pattern is a cup and handle. Now MM/Specialist have to make money, and they will bring the price down on low volume like today, it's the jungle ... Personally, October is a make it or break it kind of month for VSTM with the anticipation of VS-7375 line and RAMP 301 results ... don't fret over price movement, stick to the reasons you bought VSTM and watch OBV on a yearly chart ...
2 · Reply
sweddle
sweddle Aug. 20 at 2:22 PM
0 · Reply
PencilNeckGeek
PencilNeckGeek Aug. 20 at 2:19 PM
$VSTM Crazy that it's dropped $1 from yesterday high
0 · Reply
sweddle
sweddle Aug. 20 at 2:06 PM
0 · Reply
Crivit
Crivit Aug. 20 at 11:36 AM
$VSTM In case you didn't know: Baker Bros are back! https://fintel.io/so/us/vstm/baker-bros-advisors-lp
2 · Reply